The Role of Nuclear Medicine in the Treatment of Non-Hodgkin's Lymphoma (NHL)

References

• Zelenetz, A.D. (1999) "Radioimmunotherapy for lymphoma", Curr. Opin. Oncol., 11, 375–380.
   PubMedGoogle Scholar
• Press, W.O. (2000) "Physics for practitioners: the use of radi-olabeled monoclonal antibodies in B-cell non-Hodgkin's lympho-ma", Semin. HematoL, 37, 2–8.
   Web of Science ®Google Scholar
• Juweid, M.E. (2002) "Radioimmunotherapy of B-cell non-Hodg-kin's lymphoma: from clinical trials to clinical practice", J. Nucl. Med., 43, 1507–1529.
   Web of Science ®Google Scholar
• Safwat, A. (2000) "The role of low-dose total body irradiation in treatment of non-Hodgkin's lymphoma: a new look at an old method", Radiother. Oncol., 56, 1–8.
   Google Scholar
• Horning, S.J. (1993) "Natural history of and therapy for the indolent non-Hodgkin's lymphomas", Semin. Oncol., 20, 75–88.
   Google Scholar
• Marromatis, B.H. and Cheson, B.D. (2001) "New strategies for the treatment of indolent non-Hodgkin's lymphomas", Oncology Spectrums, 2, 706–716.
   Google Scholar
• Hagenbeek, A. and Kluin, P.M. (1999) "Non-Hodgkin's lympho-ma", In: Textbook of Malignant Haematology, edited by L. Degos, D.C. Linch, and B. Lowenberg. pp. 635–684. London: Martin Dunitz.
   Google Scholar
• Macklis, R.M., Beresford, B.A. and Humm, J.L. (1994) "Radio-biologic studies of low-dose-rate 90Y-lymphoma therapy", Cancer, 73, 966–973.
   PubMed Web of Science ®Google Scholar
• O'Donoghue, J.A. (1994) "The impact of tumor cell proliferation in radioimmunotherapy", Cancer, 73, 974–980.
   Google Scholar
• Krasner, C. and Joyce, R.M. (2001) "Zevalin: 90yttrium labeled anti-CD20 (ibritumomab tiuxetan), a new treatment for non-Hodgkin's lymphoma", Curr. Pharm. Biotechnol., 2, 341–349.
   Google Scholar
• Witzig, T.E., Flinn, I.W., Gordon, L.I., Emmanouilides, C., Czuczman, M.S., Saleh, M.N., et al. (2002) "Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with ritux-imab-refractory follicular non-Hodgkin's lymphoma", J. Clin. Oncol., 20, 3262 — 3269.
   Web of Science ®Google Scholar
• Kaminski, M.S., Tuck, M., Regan, D., Kison, P. and Wahl, R.L. (2002) "High response rates and durable remissions in patients with previously untreated, advanced-stage, follicular lymphoma treated with tositumomab and iodine tositumomab (Bexxar)" 1–131 , Blood, 100, 356a (Abstract 1381).
   Google Scholar
• Sharkey, R.M., Motta-Hennessy, C., Gansow, 0.A., Brechbiel, M.W., Fand, I., Griffiths, G.L., et(1990) "Selection of a DTPAchelate conjugate for monoclonal antibody targeting to a human colonic tumor in nude mice", Int. J. Cancer, 46, 79–85.
   PubMed Web of Science ®Google Scholar
• Wagner, H.N., Jr., Wiseman, G.A., Marcus, CS., Nabi, H.A., Nagle, C.E., Fink-Bennett, D.M., et al. (2002) "Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with (90)Y-labeled anti-CD20 monoclonal antibody", J. Nucl. Med., 43, 267–272.
   PubMed Web of Science ®Google Scholar
• Harrison, A., Walker, C.A., Parker, D., Jankowski, K.J., Cox, J.P., Craig, A.S., etal. (1991) "The in vivo release of 90Y from cyclic and acyclic ligand-antibody conjugates", Int. J. Rad. AppL Instrum. B, 18, 469–476.
   PubMedGoogle Scholar
• Kozak, R.W., Raubitschek, A., Mirzadeh, S., Brechbiel, M.W., Junghans, R.P., Gansow, 0.A., et al. (1989) "Nature of the bifunctional chelating agent used for radioimmunotherapy with yttrium-90 monoclonal antibodies: critical factors in deter-mining in vivo survival and organ toxicity", Cancer Res., 49, 2639 — 2644.
   Google Scholar
• Casey, J.L., King, D.J., Chaplin, L.C., Haines, A.M., Pedley, R.B., Mountain, A., et al. (1996) "Preparation, characterisation and tumour targeting of cross-linked divalent and trivalent anti-tumour Fab' fragments", Br. J. Cancer, 74, 1397 —1405.
   Web of Science ®Google Scholar
• Chinn, P.C., Leonard, J.E., Rosenberg, J., Hanna, N. and Anderson, D.R. (1999) "Preclinical evaluation of 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma", Int. J. Oncol., 15, 1017–1025.
   Google Scholar
• Wiseman, G.A., Kornmehl, E., Leigh, B., Erwin, W.D., Podoloff, D.A., Spies, S., et al. (2003) "Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials", J. Nucl. Med., 44, 465–474.
   Web of Science ®Google Scholar
• Wiseman, G.A., Leigh, B.R. and Erwin, W.D. (2001) "Urinary clearance of 90Y activity following Zevalin radioimmunotherapy of B-cell non-Hodgkin's lymphoma", J. Nucl. Med., 42, 268P.
   Web of Science ®Google Scholar
• Witzig, T.E., White, C.A., Gordon, L.I., Wiseman, G.A., Emma-nouilides, C., Murray, J.L., et al. (2003) "Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma", J. Clin. Oncol., 21, 1263— 1270.
   Google Scholar
• Kaminski, M.S., Zasadny, K.R., Francis, I.R., Milik, A.W., Ross, C.W., Moon, S.D., et al. (1993) "Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody", N. Engl. J. Med., 329, 459–465.
   Google Scholar
• Gates, V.L., Carey, J.E., Siegel, J.A., Kaminski, M.S. and Wahl, R.L. (1998) "Nonmyeloablative iodine-131 anti-B1 radioimmu-notherapy as outpatient therapy", J. Nucl. Med., 39, 1230–1236.
   Web of Science ®Google Scholar
• Mattes, M.J., Griffiths, G.L., Diril, H., Goldenberg, D.M., Ong, G.L. and Shih, L.B. (1994) "Processing of antibody-radioisotope conjugates after binding to the surface of tumor cells", Cancer, 73, 787— 793.
   Google Scholar
• Liu, S.Y., Eary, J.F., Petersdorf, S.H., Martin, P.J., Maloney, D.G., Appelbaum, F.R., et al. (1998) "Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue", J. Clin. Oncol., 16, 3270— 3278.
   Web of Science ®Google Scholar
• Kaminski, M.S., Estes, J., Zasadny, K.R., Francis, I.R., Ross, C.W., Tuck, M., et al. (2000) "Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience", Blood, 96, 1259–1266.
   Google Scholar
• Letvin, N.L., Zalutsky, M.R., Lambert, J.M., Chalifoux, L.V., Nadler, L.M., Schlossman, S.F., et al. (1987) "Use of radiolabeled monoclonal anti-B1 antibody for B lymphocyte imaging in rhesus monkeys", Int. J. Rad. AppL Instrum. B, 14, 99 — 105.
   PubMedGoogle Scholar
• Kaminski, M.S., Fig, L.M., Zasadny, K.R., Koral, K.F., DelRo-sario, R.B., Francis, I.R., et al. (1992) "Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma", J. Clin. Oncol., 10, 1696–1711.
   PubMed Web of Science ®Google Scholar
• Kaminski, M.S., Zelenetz, AD., Press, 0.W., Saleh, M., Leonard, J., Fehrenbacher, L., et al. (2001) "Pivotal study of iodine 113! tositumomab for chemotherapy-refractory low-grade or trans-formed low-grade B-cell non-Hodgkin's lymphomas", J. Clin. Oncol., 19, 3918 — 3928.
   Google Scholar
• Davis, TA., Kaminski, M.S., Leonnard, J.P., Gregory, S.A., Wahl, R., Hsu, F.J., et al. (2001) "Results of a randomized study of Bmcar (tositumomab and Iodine I 131 tositumomab) vs unlabelled tositumomab in patients with relapsed or refractory low-grade or transformed non-Hodgkin's lymphoma (NHL)", Blood, 98, 843a (Abstract 3503).
   Google Scholar
• Davies, A.J., Radford, J.A., Britton, K., Howell, S., Deakin, D.P., Micallef, IN., et al. (2001) "A phase II study of Bmcar (tositumomab and tositumomab) for patients at 1st or 2nd recurrence of B-cell non Hodgkin's lymphoma", 1–131Proc. Am. Soc. Clin. Oncol., 20, 286a (Abstract 1142).
   Google Scholar
• Wiseman, G., Leigh, B. and Witzig, T. (2001) "Radiation exposure is very low to family members of patients treated with yttrium-90 Zevalin anti-CD20 monoclonal antibody therapy for lymphoma", Eur. J. Nucl. Med., 28, 1198 (Abstract PS 1479).
   Google Scholar
• Rutar, F.J., Augustine, S.C., Colcher, D., Siegel, J.A., Jacobson, D.A., Tempero, M.A., et al. (2001) "Outpatient treatment with (131)I-anti-B1 antibody: radiation exposure to family members", J. Nucl. Med., 42, 907–915.
   Web of Science ®Google Scholar
• Witzig, T.E., Gordon, L.I., Cabanillas, F., Czuczman, M.S., Emmanouilides, C., Joyce, R., et al. (2002) "Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunother-apy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodg-kin's lymphoma", J. Clin. Oncol., 20, 2453–2463.
   Web of Science ®Google Scholar
• Wiseman, GA., Gordon, L.I., Multani, P.S., Witzig, T.E., Spies, S., Bartlett, N.L., et al. (2002) "Ibritumomab tiuxetan radioimmu-notherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial", Blood, 99, 4336–4342.
   Google Scholar
• Vose, J.M., Wahl, R.L., Saleh, M., Rohatiner, AZ., Knox, Si., Radford, J.A., et al. (2000) "Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas", J. Clin. Oncol., 18, 1316–1323.
   Web of Science ®Google Scholar